Company to deliver a poster presentation on clinical data demonstrating sustained remissionfollowing immune checkpoint inhibitor therapy with or after leronlimab treatmentin patients with metastatic or locally advanced triple-negative breast cancer VANCOUVER, Washington, Nov. 24, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic p ...

Core Insights - CytoDyn Inc. is set to present clinical data at the San Antonio Breast Cancer Symposium, showcasing sustained remission in patients with metastatic triple-negative breast cancer (mTNBC) following treatment with leronlimab and immune checkpoint inhibitors [1][3] Company Overview - CytoDyn is a clinical-stage oncology company focused on advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, with potential applications in various cancers, including mTNBC and colorectal cancer [1][6] Clinical Data Presentation - Dr. Milana V. Dolezal from Stanford University will present a poster detailing the prolonged survival of mTNBC patients treated with leronlimab in combination with PD-L1/PD-1 immune checkpoint inhibitors, highlighting the upregulation of PD-L1 levels [2][9] - The poster presentation is scheduled for December 12, 2025, from 12:30 PM to 2:00 PM CST at the Exhibit Hall [9] Treatment Efficacy - The use of leronlimab has been associated with increased PD-L1 levels, which may enhance the efficacy of immune checkpoint inhibitors in mTNBC patients, particularly those with low PD-L1 expression [2][3]